DexCom, Inc.
DXCMHealthcareNASDAQMedical Devices · Last scanned Jun 3, 2026
Scan Results
Daily timeframePart of the healthcare sector, DexCom, Inc. (DXCM) is listed under Medical Devices. The $28.34B market capitalization puts DXCM squarely in large-cap range for its industry. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Market Cap
$28.34B
Beta
1.40
P/E (TTM)
31.52
P/E (Fwd)
23.94
EPS (TTM)
$2.33
EPS (Fwd)
$3.07
ROE
35.6%
ROA
9.7%
Cash
$2.42B
Total Debt
$1.38B
Free CF
$1.06B
52W Change
-14.2%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $2.42B in cash comfortably exceeding the $1.38B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $1.06B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 35.6% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 9.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $2.91B (2022) to $4.66B (2025), reflecting a 60% increase over the period.
Investors considering DexCom, Inc. should weigh the typical risks associated with DXCM's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence DexCom, Inc.'s trajectory.